Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Up Front MattersEditorials
You have accessRestricted Access

Circulating Anti-PLA2R Autoantibodies to Monitor Immunological Activity in Membranous Nephropathy

Paolo Cravedi, Piero Ruggenenti and Giuseppe Remuzzi
JASN August 2011, 22 (8) 1400-1402; DOI: https://doi.org/10.1681/ASN.2011060610
Paolo Cravedi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piero Ruggenenti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giuseppe Remuzzi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

Experimental and human data converge to indicate that deposition along the glomerular basement membrane of immunoglobulins produced by autoreactive B cells may initiate a sequence of events resulting in complement activation,1 impaired sieving function of the glomerular capillary wall and the pore-forming slit diaphragm,2 and eventual proteinuria that characterizes idiopathic membranous nephropathy (IMN).3 Thus, treatment with agents that selectively inhibit the production of nephritogenic antibodies would likely be the most effective intervention to prevent one of the earliest steps in the sequence of pathogenic events underlying progressive renal dysfunction in IMN.

Until the early nineties, however, no specific anti-B cell therapies were available and therapeutic approaches to IMN mostly relied on steroids and cytotoxics with or without calcineurin inhibitors. Such agents have significant nonspecific toxicity. On the other hand, kidney survival in patients who do not undergo spontaneous remission4 has not been substantially improved over the last 30 yr, to the extent that as many as 40% of patients with IMN still progress to end-stage kidney disease despite treatment.5

Rituximab, a monoclonal antibody against the CD20 antigen present on B cells, was approved by the Food and Drug Administration in 1997 for the treatment of relapsing or refractory non-Hodgkin's lymphoma and, more recently, for patients with rheumatoid arthritis.6 Since the CD20 antigen is not expressed on hematopoietic stem cells, normal plasma cells or other normal tissues, selective B cell depletion by rituximab therapy soon surfaced as a potential, specific therapeutic option for IMN.

With this background, rituximab was initially tested in a small cohort of eight IMN patients with severe nephrotic syndrome unresponsive to prolonged angiotensin converting enzyme (ACE) inhibitor therapy.7 Rituximab infusion was well tolerated and led to a significant reduction in proteinuria and amelioration of nephrotic syndrome in all of the cases. The effect was sustained over one year of follow-up and was associated with a reduction in body weight, diastolic BP, and serum cholesterol.8 Since this initial experience, other groups have consistently reported the efficacy of rituximab in reducing proteinuria in patients with IMN and nephrotic syndrome.9,10 In confirmation of the superior effectiveness of interventions targeted to specific pathogenetic mechanisms compared with nonspecific immunosuppression, when used as second-line treatment, rituximab safely and persistently reduced proteinuria in IMN patients who had previously failed to respond to steroids, alkylating agents, or calcineurin inhibitors, or who had relapsed after transient remission.11,12

Finding that selective B cell depletion lowered proteinuria in patients with IMN points to a pathogenetic role of antibody-producing lymphocytes in this disease. While renal antigens have been elusive until recently, in 2002, neutral endopeptidase (NEP) was identified as the target antigen in newborns with NEP-deficient mothers, providing evidence for the notion that a human podocyte antigen could serve as a target for nephritogenic antibodies.13 More recently, antibodies against cationic bovine serum albumin have been implicated in pediatric cases of IMN.14 Finally, M-type phospholipase A2 receptor (PLA2R) has been shown as the first podocyte antigen involved in IMN in adults.15 Detection of these autoantibodies might help in differentiating primary from secondary forms of the disease and monitoring responses to treatment.

In this issue of JASN, Beck et al. evaluated the relationship between changes in serum anti-PLA2R autoantibody levels and response to rituximab therapy in 35 adult patients with IMN. Circulating autoantibodies were detected in 80% of patients at baseline, and their titers decreased after rituximab therapy in the majority of them.16 Importantly, reduction of anti-PLA2R autoantibody levels anticipated the decline of proteinuria and, in one patient with a relapse of proteinuria, the reemergence of the autoantibody in the circulation preceded recurrence of disease.

According to these findings, monitoring anti-PLA2R autoantibodies might help titrating IMN therapy to the activity level of disease. In patients with declining autoantibody titer despite stable proteinuria, one may choose to wait to see whether a sustained normalization of antibody titer simply precedes a beneficial effect on proteinuria without need for further intervention. Information on the autoantibody titer would also be valuable in selecting patients for clinical trials of immunosuppressive interventions to avoid the inclusion of subjects with less active disease. On the other hand, some degree of residual proteinuria can persist even after prolonged remission of autoimmune response, as a result of chronic glomerular damage induced by the initial immunological insult that progressed independently of the immune process. This is in line with results of a previous report showing that the severity of chronic renal lesions on biopsy predicts the degree of residual proteinuria after rituximab therapy.17 In these cases, nonimmune nephroprotective strategies targeting the renin angiotensin system should be implemented to maximally reduce proteinuria.

According to the findings by Beck et al., however, approximately one third of patients with IMN might be expected to have a partial proteinuria remission despite persistently high levels of anti-PLA2R autoantibodies. Similar findings have has been reported in patients with antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis, where clinical response is not always associated with ANCA titer decline.18 This finding also suggests that, in these clinical conditions, autoantibodies other than anti-PLA2R or antineutrophil cytoplasmic antibodies may be involved in the autoimmune response. On the other hand, it can be speculated that rituximab also reduces the proteinuria of IMN by immune-independent mechanisms. It is also possible that rituximab has a direct action on podocytes, as was recently shown in focal segmental glomerulosclerosis (FSGS), where the antibody appears to target sphingomyelin phosphodiesterase acid-like 3b, preventing the remodeling of the cytoskeleton.19 It is unlikely, however, that a direct effect on podocyte explains the beneficial effect of rituximab in IMN due to the strong correlation between antibody titer and proteinuria documented in the paper under consideration here.

In analogy with other autoimmune diseases such as thrombotic thrombocytopenic purpura, where dosing of pathogenic anti-ADAMTS 13 autoantibodies in the circulation, in combination with markers of microangiopathic hemolysis, may help to monitor disease activity and guide specific intervention20 in patients with IMN, combined assessment of circulating anti-PLA2R autoantibodies and proteinuria may be instrumental in optimizing patient care and hopefully improving long term outcomes.

DISCLOSURES

None.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related article, “Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy,” on pages 1543–1550.

  • Copyright © 2011 by the American Society of Nephrology

REFERENCES

  1. 1.↵
    1. Sacks S,
    2. Zhou W
    : New boundaries for complement in renal disease. J Am Soc Nephrol 19: 1865–1869, 2008
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Gagliardini E,
    2. Conti S,
    3. Benigni A,
    4. Remuzzi G,
    5. Remuzzi A
    : Imaging of the porous ultrastructure of the glomerular epithelial filtration slit. J Am Soc Nephrol 21: 2081–2089, 2010
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Ronco P,
    2. Debiec H
    : Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J Am Soc Nephrol 21: 564–569, 2010
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Polanco N,
    2. Gutierrez E,
    3. Covarsi A,
    4. Ariza F,
    5. Carreno A,
    6. Vigil A,
    7. Baltar J,
    8. Fernandez-Fresnedo G,
    9. Martin C,
    10. Pons S,
    11. Lorenzo D,
    12. Bernis C,
    13. Arrizabalaga P,
    14. Fernandez-Juarez G,
    15. Barrio V,
    16. Sierra M,
    17. Castellanos I,
    18. Espinosa M,
    19. Rivera F,
    20. Oliet A,
    21. Fernandez-Vega F,
    22. Praga M
    : Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21: 697–704, 2010
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Ruggenenti P,
    2. Cravedi P,
    3. Remuzzi G
    : Latest treatment strategies for membranous nephropathy. Expert Opin Pharmacother 8: 3159–3171, 2007
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Taylor RP,
    2. Lindorfer MA
    : Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 20: 444–449, 2008
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Remuzzi G,
    2. Chiurchiu C,
    3. Abbate M,
    4. Brusegan V,
    5. Bontempelli M,
    6. Ruggenenti P
    : Rituximab for idiopathic membranous nephropathy. Lancet 360: 923–924, 2002
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Ruggenenti P,
    2. Chiurchiu C,
    3. Brusegan V,
    4. Abbate M,
    5. Perna A,
    6. Filippi C,
    7. Remuzzi G
    : Rituximab in idiopathic membranous nephropathy: A one-year prospective study. J Am Soc Nephrol 14: 1851–1857, 2003
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Bomback AS,
    2. Derebail VK,
    3. McGregor JG,
    4. Kshirsagar AV,
    5. Falk RJ,
    6. Nachman PH
    : Rituximab therapy for membranous nephropathy: A systematic review. Clin J Am Soc Nephrol 4: 734–744, 2009
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Fervenza FC,
    2. Cosio FG,
    3. Erickson SB,
    4. Specks U,
    5. Herzenberg AM,
    6. Dillon JJ,
    7. Leung N,
    8. Cohen IM,
    9. Wochos DN,
    10. Bergstralh E,
    11. Hladunewich M,
    12. Cattran DC
    : Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73: 117–125, 2008
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Cravedi P,
    2. Sghirlanzoni MC,
    3. Marasa M,
    4. Salerno A,
    5. Remuzzi G,
    6. Ruggenenti P
    : Efficacy and safety of rituximab second-line therapy for membranous nephropathy: A prospective, matched-cohort study. Am J Nephrol 33: 461–468, 2011
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Segarra A,
    2. Praga M,
    3. Ramos N,
    4. Polanco N,
    5. Cargol I,
    6. Gutierrez-Solis E,
    7. Gomez MR,
    8. Montoro B,
    9. Camps J
    : Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 4: 1083–1088, 2009
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Debiec H,
    2. Guigonis V,
    3. Mougenot B,
    4. Decobert F,
    5. Haymann JP,
    6. Bensman A,
    7. Deschenes G,
    8. Ronco PM
    : Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 346: 2053–2060, 2002
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Debiec H,
    2. Lefeu F,
    3. Kemper MJ,
    4. Niaudet P,
    5. Deschenes G,
    6. Remuzzi G,
    7. Ulinski T,
    8. Ronco P
    : Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 364: 2101–2110, 2011
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Beck LH Jr.,
    2. Bonegio RG,
    3. Lambeau G,
    4. Beck DM,
    5. Powell DW,
    6. Cummins TD,
    7. Klein JB,
    8. Salant DJ
    : M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11–21, 2009
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Beck LH,
    2. Fervenza FC,
    3. Beck DM,
    4. Bonegio RGB,
    5. Malik FA,
    6. Erickson SB,
    7. Cosio FG,
    8. Cattran DC,
    9. Salant DJ
    : Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22: 1543–1550, 2011
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Ruggenenti P,
    2. Chiurchiu C,
    3. Abbate M,
    4. Perna A,
    5. Cravedi P,
    6. Bontempelli M,
    7. Remuzzi G
    : Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 1: 738–748, 2006
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Stone JH,
    2. Merkel PA,
    3. Spiera R,
    4. Seo P,
    5. Langford CA,
    6. Hoffman GS,
    7. Kallenberg CG,
    8. St Clair EW,
    9. Turkiewicz A,
    10. Tchao NK,
    11. Webber L,
    12. Ding L,
    13. Sejismundo LP,
    14. Mieras K,
    15. Weitzenkamp D,
    16. Ikle D,
    17. Seyfert-Margolis V,
    18. Mueller M,
    19. Brunetta P,
    20. Allen NB,
    21. Fervenza FC,
    22. Geetha D,
    23. Keogh KA,
    24. Kissin EY,
    25. Monach PA,
    26. Peikert T,
    27. Stegeman C,
    28. Ytterberg SR,
    29. Specks U
    ; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221–232, 2010
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Fornoni A,
    2. Sageshima J,
    3. Wei C,
    4. Merscher-Gomez S,
    5. Aguillon-Prada R,
    6. Jauregui AN,
    7. Li J,
    8. Mattiazzi A,
    9. Ciancio G,
    10. Chen L,
    11. Zilleruelo G,
    12. Abitbol C,
    13. Chandar J,
    14. Seeherunvong W,
    15. Ricordi C,
    16. Ikehata M,
    17. Rastaldi MP,
    18. Reiser J,
    19. Burke GW 3rd.
    : Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 3: 85ra46, 2011
  20. 20.↵
    1. Bresin E,
    2. Gastoldi S,
    3. Daina E,
    4. Belotti D,
    5. Pogliani E,
    6. Perseghin P,
    7. Scalzulli PR,
    8. Paolini R,
    9. Marceno R,
    10. Remuzzi G,
    11. Galbusera M
    : Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost 101: 233–238, 2009
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 22 (8)
Journal of the American Society of Nephrology
Vol. 22, Issue 8
1 Aug 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Circulating Anti-PLA2R Autoantibodies to Monitor Immunological Activity in Membranous Nephropathy
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Circulating Anti-PLA2R Autoantibodies to Monitor Immunological Activity in Membranous Nephropathy
Paolo Cravedi, Piero Ruggenenti, Giuseppe Remuzzi
JASN Aug 2011, 22 (8) 1400-1402; DOI: 10.1681/ASN.2011060610

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Circulating Anti-PLA2R Autoantibodies to Monitor Immunological Activity in Membranous Nephropathy
Paolo Cravedi, Piero Ruggenenti, Giuseppe Remuzzi
JASN Aug 2011, 22 (8) 1400-1402; DOI: 10.1681/ASN.2011060610
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • DISCLOSURES
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • View PDF

More in this TOC Section

Up Front Matters

  • COVID-19 and APOL1: Understanding Disease Mechanisms through Clinical Observation
  • The Aftermath of AKI: Recurrent AKI, Acute Kidney Disease, and CKD Progression
  • Sphingosine-1-Phosphate Metabolism and Signaling in Kidney Diseases
Show more Up Front Matters

Editorials

  • The Road Ahead for Research on Air Pollution and Kidney Disease
  • Missing Self and DSA—Synergy of Two NK Cell Activation Pathways in Kidney Transplantation
  • Animal Model of Pregnancy after Acute Kidney Injury Mirrors the Human Observations
Show more Editorials

Cited By...

  • Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy
  • Membranous nephropathy
  • Rituximab in Idiopathic Membranous Nephropathy
  • Google Scholar

Similar Articles

Related Articles

  • Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire